WHX Labs Kuala Lumpur, a premier Southeast Asian healthcare event, concluded successfully in Kuala Lumpur from July 16-18, 2025. Attracting over 10,000 professionals from 60 countries,YZY MED emerged as a standout participant with its innovative product portfolio, securing multiple collaborations—particularly for its CTC (Circulating Tumor Cell) devices and FISH (Fluorescence In Situ Hybridization) product lines.
Prior to the event, YZY MED’s overseas sales team visited local clients, toured cancer hospitals, conducted technical exchanges, and gained insights into market needs.
The CTCBIOPSY® Circulating Tumor Cell Sorter A10 drew numerous clinical experts with its 85% high detection rate and fully automated capture technology. Its breakthrough application in dynamic monitoring of solid tumors like glioma—such as predicting recurrence earlier than imaging—sparked lively discussions, with several local enterprises and agents planning to evaluate the CTC sorter for potential introduction or collaboration. The CDx companion diagnostics product line not only covers high-incidence cancers like lung and colorectal cancer but also demonstrates full-cycle support capabilities for precision medicine.
This exhibition appearance confirmed that YZY MED’s technical solutions are highly aligned with global (especially Southeast Asian) needs in cancer diagnostics. Its products’ advantages in detection rate and clinical utility align with the development trend of precision medicine. Looking ahead, YZY MED will continue to deepen cooperation with global partners, bringing more accurate and efficient diagnostic solutions to patients in Southeast Asia and beyond.
